FARMINGDALE, N.Y., Sept. 8 /PRNewswire/ -- Misonix, Inc. (Nasdaq: MSON), a developer of state of the art, ultrasonic medical device technology, which worldwide is used for acute health conditions, has entered into a new, three year, exclusive distribution agreement with Cormedica s.a.s. Based near Lyon, France, Cormedica will distribute the BoneScalpel™ Ultrasonic Bone Cutter. The agreement provides Cormedica with the rights to sell throughout France, and includes annual minimum purchase requirements.
Cormedica has a lengthy record of successful new product introductions and long history as a distributor of high tech medical devices and capital equipment, with special emphasis on Neuro, Spine, and Maxillo-facial Surgery.
The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the safety issues often associated with rotary sharps.
"Misonix is pleased to add Cormedica to our growing family of specialty distributors. Their reputation as a successful distributor of medical equipment in France is well known to us," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Their success in introducing state-of-the-art medical devices was appealing to Misonix and we are excited that they will be selling BoneScalpel through their extensive neuro-spine distribution network."
About Misonix:Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
With the exception of historical information contained in this press release, content herein may contain "forward-looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.Investor Relations Contact:Kevin McGrath/Cameron Associates, Inc.212-245-4577Kevin@cameronassoc.com
|SOURCE Misonix, Inc.|
Copyright©2010 PR Newswire.
All rights reserved